Perspectives
Nature Reviews Drug Discovery 6, 287-293 (April 2007) | doi:10.1038/nrd2251
Article series: Biomarkers
Outlook: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
Mark R. Trusheim1, Ernst R. Berndt1 & Frank L. Douglas1 About the authors
Abstract
The potential to use biomarkers for identifying patients that are more likely to benefit or experience an adverse reaction in response to a given therapy, and thereby better match patients with therapies, is anticipated to have a major effect on both clinical practice and the development of new drugs and diagnostics. In this article, we consider current and emerging examples in which therapies are matched with specific patient population characteristics using clinical biomarkers — which we call stratified medicine — and discuss the implications of this approach to future product development strategies and market structures.
Author affiliations
-
Mark R. Trusheim, Ernst R. Berndt and Frank L. Douglas are at the MIT Center for Biomedical Innovation, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139-4307, USA.
Email: mtrusheim@cobioconsulting.com; Email: eberndt@mit.edu; Email: fldoug@mit.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineagesNature Biotechnology Research (01 Sep 2004)
L -Arginine decreases fluid-percussion injury-induced neuronal nitrotyrosine immunoreactivity in ratsJournal of Cerebral Blood Flow & Metabolism Original Article
Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalizationNature Neuroscience Article (01 Dec 2000)
See all 5 matches for Research
